The transition through menopause often brings unwelcome changes, including a tendency toward weight gain that can increase the risk of heart disease and metabolic problems. Now, a recent study suggests a surprising boost to weight loss efforts for women navigating this life stage: combining hormone therapy with a widely used obesity medication. Researchers at the Mayo Clinic found that postmenopausal women shed significantly more weight when using tirzepatide alongside hormone therapy compared to those using the medication alone.
For many women, the midlife years present a challenge to maintaining a healthy weight. Hormonal shifts during menopause play a significant role, contributing to increased body fat and a heightened risk of obesity. This, in turn, can exacerbate existing health concerns and introduce new ones. Tirzepatide, sold under the brand names Mounjaro and Zepbound, has emerged as a highly effective treatment for obesity, prompting scientists to investigate whether its effects could be influenced by concurrent hormone therapy.
The Mayo Clinic and Wayne State University researchers analyzed health data from 120 women over the age of 50 who were either overweight or obese and using tirzepatide. Participants were monitored for 18 months. The study revealed a clear difference between the groups: 40 women were also receiving hormone therapy, while 80 were using tirzepatide as a standalone treatment.
Hormone Therapy Appears to Enhance Weight Loss Results
After 15 months of treatment, women who combined tirzepatide with hormone therapy experienced a substantially greater total body weight loss than those who used tirzepatide alone. On average, women in the combination group lost 19.2% of their initial body weight, compared to 14% in the group using only tirzepatide. While a 5.2 percentage point difference may seem modest, the researchers emphasize that it is “statistically significant.” Notably, a substantial portion of the women combining both therapies achieved a total weight loss of 30% to 35% within the 15-month period.
Beyond weight loss, both groups showed improvements in blood sugar levels, blood pressure and liver enzyme concentrations. However, women using hormone therapy in addition to tirzepatide experienced further reductions in diastolic blood pressure and triglyceride levels. These findings build upon previous research, including a 2024 study that demonstrated similar benefits when hormone therapy was combined with semaglutide, another GLP-1 medication.
That earlier research, conducted by some of the same scientists, found that after 12 months, a larger proportion of postmenopausal women using both semaglutide and hormone therapy achieved a total weight loss of 10% or more compared to those using semaglutide alone.
Further Research Needed to Confirm Findings
The researchers are now planning larger, randomized controlled trials to further investigate the potential synergy between hormone therapy and tirzepatide. These studies will aim to determine whether the observed benefits hold up under more rigorous testing and confirm whether the combination truly leads to significantly greater weight loss.
“In postmenopausal women with overweight or obesity, concomitant leverage of hormone therapy was associated with greater weight loss and improved cardiometabolic outcomes during treatment with tirzepatide,” the study authors concluded. “These findings suggest that hormone therapy may enhance the therapeutic effects of tirzepatide in this population.”
Regina Castaneda, the lead author of the study and a researcher at the Mayo Clinic’s Center for Women’s Health Research, stated, “The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact.”
Addressing a Common Challenge for Women in Midlife
Menopause is a transformative period marked by significant physiological and hormonal changes. These shifts can lead to a range of challenging symptoms, including fatigue, hot flashes, night sweats, and sleep disturbances. Hormone therapy can help manage these symptoms and offer some protection against menopause-related diseases like osteoporosis and heart disease. While some studies suggest hormone replacement therapy may help prevent weight gain later in life, its impact on promoting weight loss has been less clear.
“Millions of women struggle with weight gain in midlife, and the reality is that we don’t know what the answer is,” Castaneda said at the North American Menopause Society’s Annual Meeting last fall, where she presented the team’s recent findings.
Scientists note that weight gain is common not only in women experiencing perimenopause and postmenopause but also in those with reproductive issues affecting their ovaries and uterus. Women with polycystic ovary syndrome (PCOS), for example, are more prone to insulin resistance, which can increase the risk of type 2 diabetes and contribute to weight gain.
This research offers a potential new avenue for addressing weight management in this population, but it’s crucial to remember that individual responses to medication can vary. The decision to use hormone therapy and tirzepatide should be made in consultation with a healthcare provider, considering individual health history and potential risks and benefits.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Further research is expected to shed more light on the optimal use of these therapies and their long-term effects. The next step for the Mayo Clinic team is to launch the larger, randomized controlled trials needed to confirm these promising initial findings. Share your thoughts on this research in the comments below, and consider sharing this article with others who may locate it helpful.
